A molecular basis for the effectiveness of this agent emerged from evidence showing that defects in the tumor suppressor genes BRCA1 and BRCA2, which are prevalent in ovarian cancer, cause homologous recombination DNA repair (HR)-deficiency in cancer cells, and increased sensitivity to the cytotoxic effects of platinum compounds. This evidence concerns the gene BRCA1 and ovarian carcinoma.